A New Prescription: Can Tech and Transparency Finally Fix Pharmacy Benefits?

MINNEAPOLIS, MN – June 16, 2026 – In the complex and often obscure world of American healthcare, a new partnership was announced that, on the surface, seems like standard corporate news. Tredium Solutions, a technology provider, will supply its claims platform to Scripius, a Pharmacy Benefit Manager (PBM). But for anyone who has watched their insurance costs climb or stared in confusion at a pharmacy bill, this collaboration is more than just a press release. It's a signal of a seismic shift in a $447 billion industry that has operated in the shadows for far too long. The partnership represents a direct challenge to the status quo, leveraging technology to deliver on a promise the healthcare system has long struggled to keep: transparency.

The Opaque World of Pharmacy Benefits

To understand the significance of this deal, one must first understand the immense power wielded by Pharmacy Benefit Managers. PBMs are the middlemen who manage prescription drug benefits on behalf of health insurers, large employers, and Medicare. In theory, their job is to leverage the purchasing power of millions of members to negotiate lower drug prices from manufacturers.

The data, however, reveals a stark concentration of power. The U.S. PBM market is dominated by just three major players—CVS Caremark, Express Scripts, and OptumRx—which collectively process an estimated 80% of all prescription claims. For years, these giants have faced a barrage of criticism from lawmakers, employers, and patient advocates. The core of the complaint is a profound lack of transparency. Critics argue that complex rebate systems, where drugmakers pay PBMs to get their products on an insurer's preferred list (or formulary), actually incentivize higher list prices. Much of the money from these rebates often doesn't make its way back to the employers or patients, but is instead retained by the PBMs through opaque contracts and practices like "spread pricing"—charging an insurer more for a drug than they reimburse the pharmacy.

This environment has left employers, who pay the bills, feeling powerless and patients, who need the medicine, paying more at the counter. The entire system has become a black box, making it nearly impossible to know the true cost of a drug.

A Model Built for a New Era

It is into this landscape of frustration and scrutiny that Scripius enters, positioning itself as a disruptor. Its business model is built on the very principles the industry is accused of lacking: transparency and a focus on the "lowest net cost." This isn't just a marketing slogan; it represents a fundamentally different way of doing business. A transparent PBM typically operates on a "pass-through" pricing model, where the client pays the exact price the PBM negotiated with the pharmacy, plus a simple, flat administrative fee. All manufacturer rebates are passed directly back to the health plan or employer.

This approach is no longer just a niche alternative; it's rapidly becoming a market and regulatory necessity. The recently passed Consolidated Appropriations Act, 2026, includes sweeping PBM reforms that will, by 2029, mandate that PBMs pass 100% of rebates back to employer health plans and provide unprecedented levels of disclosure. Scripius's strategy appears to be an attempt to get ahead of the curve, building its entire operation around the principles that will soon be the law of the land.

"At Scripius, we’re changing how pharmacy benefits should work—transparent and aligned to customer’s goals,” said Eric Cannon, the company's chief commercial officer and general manager, in a statement. The selection of a technology partner is crucial to realizing that vision.

The Technology Powering the Change

This is where Tredium Solutions comes in. A commitment to transparency is meaningless without the infrastructure to execute it. Legacy systems used by many larger players are often clunky and ill-suited for the kind of granular, real-time reporting that true transparency requires. Tredium provides what the press release calls a "modern, cloud-based architecture," and for once, this tech jargon is the heart of the story.

A cloud-based platform provides the scalability and flexibility Scripius needs to serve a diverse client base, from commercial health plans to complex Medicare and Medicaid programs. More importantly, it provides the operational foundation for transparency. Such systems are designed to process claims in real-time, track every dollar, and generate detailed reports that can show a client exactly where their money is going. This data visibility allows Scripius to prove its "lowest net cost" model, demonstrating savings and demystifying the tangled web of pharmaceutical pricing. By providing white-label solutions that include access to a pharmacy network and rebate management, Tredium allows Scripius to focus on its core mission while leveraging a robust, pre-built technological engine.

The Ripple Effect on Your Wallet

While the deal is between two corporations, its potential impact extends to nearly everyone. For the self-funded employers who provide health insurance for millions of Americans, the shift to a transparent PBM model could mean significant cost savings and more predictable healthcare budgets. With clear data, benefits managers can make more informed decisions about plan design, reducing waste and ensuring they are not overpaying for prescriptions. This also helps them fulfill their fiduciary duty to act in the best financial interest of their employees.

For health plans, the advanced reporting capabilities offered by the Tredium platform are essential for navigating the new regulatory landscape and ensuring compliance, avoiding hefty fines.

Ultimately, the goal is to have these savings trickle down to the individual. When the true cost of drugs is lower and rebates are passed through, it can lead to lower premiums, deductibles, and co-pays at the pharmacy counter. For patients, particularly those managing chronic conditions, more affordable medication can be the difference between adhering to a treatment plan and rationing pills, directly impacting health outcomes.

This partnership is not a silver bullet for America's healthcare cost crisis. However, it is a powerful illustration of how market forces, spurred by regulatory pressure and enabled by modern technology, are converging to challenge a powerful and entrenched industry. The dominant PBMs, now facing both legislative mandates and nimble competitors, will be forced to respond. Whether they choose to adapt their models, acquire the innovators, or attempt to out-compete them, it is clear that the era of the PBM black box is coming to an end. This move by Scripius and Tredium is a bet that the future of pharmacy benefits will be built on data, not deals made in the dark.